Skip to main content
. 2017 Mar 31;8(21):34836–34843. doi: 10.18632/oncotarget.16753

Figure 2.

Figure 2

Decision curve analysis of predicting significant PCa with base model vs. base model + MRI + PZ-ratio in all PSA group (A) and patients with PSA of 4–10 ng/ml (B).